Breast NeoplasmsPhase 2NCT00291304
Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
A Phase 2 study testing MRI in people with Breast Neoplasms, run by AHS Cancer Control Alberta at 1 site in Canada.
Trial summary
Magnetic Resonance Imaging (MRI) is a well known imaging tool for the investigation and diagnosis of breast cancer, used in addition to breast mammograms and ultrasound. Recent publications suggest that MRI may be the best test to use in women who have very dense breasts, have a family history of breast cancer and… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Neoplasms
- What is being tested?
- MRI
- Type of treatment
- Surgery or procedure
- How many people
- 72 participants
- Where
- 1 siteCanada
- Study dates
- Mar 2006to Jan 2010
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- females 18 years or older
- females referred to Dr. Kelly Dabbs for breast cancer surgery with pathology positive for breast carcinoma, any subtype
Who cannot join
- pacemakers
- aneurysm clips
- cochlear implants
- epicardial pacemaker wires
- neural stimulators, etc.
- significant claustrophobia
- significant obesity that would not enable the patient to fit in the scanner
- pregnancy or breast feeding
Trial locations and contacts
1 site in 1 country.
About this study
Magnetic Resonance Imaging (MRI) is a well known imaging tool for the investigation and diagnosis of breast cancer, used in addition to breast mammograms and ultrasound. Recent publications suggest that MRI may be the best test to use in women who have very dense breasts, have a family history of breast cancer and have had breast cancer and were treated with breast saving measures. MRI has been shown to be a better tool to show multiple breast cancer spots than mammography or ultrasound. The radiologists and the radiology students will have the opportunity to review the MRI scans along with the breast ultrasound and mammography films and the pathology reports from the breast cancer surgery completed at the CCI. This may enable them to learn how the various subtypes of breast cancer look on MRI. The goal is: 1) to gain good breast MRI expertise, giving the Radiology residents a complete diagnostic program. 2) to develop good MRI breast experience, enabling the Cross Cancer Institute to be the centre of excellence for Breast MRI for northern Alberta.
Read the detailed description
Background Information
In addition to the gold standard imaging of mammography and breast ultrasound, magnetic resonance imaging (MRI) has become a well established investigational modality for the diagnosis and staging of breast cancer. MRI demonstrates increased sensitivity and specificity relative to both mammography and breast ultrasound in the screening of women with an increased risk of breast cancer development (i.e. familial history of disease and / or genetic predisposition) and those who have very dense breast tissue. MRI has also proved to be very sensitive in the detection of multi-focal, multi-centric breast lesions, permitting the accurate staging of disease. However, despite this demonstrated efficacy, the standardization of MRI studies from one Institution to another is often difficult as each Institution will have a standard breast protocol with sequences set in accordance to the manufacturer of the machine and the manner in which the breast examinations have been designed.
At the Cross Cancer Institute (CCI) a breast MRI protocol based on the technical procedures recommended in the literature and personal scanning experience has been developed. However, due to the limited number of patients undergoing breast MRI examinations, our current experience is limited relative to the level of expertise demonstrated in the interpretation of breast ultrasound and mammographic scans. Fortunately, we now have the opportunity to obtain MRI - pathology correlation as Dr. Kelly Dabbs is performing on site breast cancer surgery at the CCI. We propose to obtain an MRI examination of all consented patients prior to their surgical procedure. The MRI results of each patient will then be compared to previous breast imaging (mammography and breast ultrasound) and histopathological specimens to determine the correlative accuracy of MRI with these techniques. To assess whether the size, grade, and presence of lymphovascular invasion or associated ductal carcinoma in situ influence the accuracy of MR imaging, all breast carcinoma subtypes will be included in this study.
As a teaching hospital, the CCI provides mammographic and breast ultrasound training to the Residents and the Diagnostic Radiology Program at the University of Alberta. Although breast MRI should be part of this training program, we currently do not have the necessary volume of breast MRI scans to provide Residents with adequate experience in this modality. The establishment of a breast MRI protocol, one which refers eligible CCI breast cancer patients for a pre-surgery MRI examination, will promote the development of expertise in this area, provide Residents with a comprehensive Breast program and keep the CCI at the leading edge of breast cancer care.
Objectives
Primary Objective: to assess how the MRI of the breast correlates to a standard of care which includes biopsy, surgery, breast ultrasound and mammography.
Secondary Objective: to assess how the MRI correlates to the breast cancer pathology collected at the CCI.
Study Design
A research study is proposed with the above information in mind, whereby Dr. Kelly Dabbs refers consented surgical patients with known breast carcinoma for a pre-surgical breast MRI. The MRI results will then be reviewed along with the mammograms and breast ultrasounds and then correlated to pathology findings. The intent will be to correlate all of the various sub-types of breast carcinoma with MRI, as well as to assess whether or not MRI demonstrates changes dependent upon the extent lymphovascular invasion, the presence of associated ductal carcinoma in situ and the size, cellular composition and grade of the cancer.
Dr. Dabbs will explain the study rational and give the patient a copy of Informed Consent and, for those patients who are willing to undergo the procedure, schedule a MRI at the CCI. It is our aim to accrue 50 patients per year for two years, for a total of 100 patients.
Inclusion / Exclusion Criteria
Inclusion criteria:
- Females ? 18 years of age
- Females referred to Dr. Kelly Dabbs for breast cancer surgery who have pathology positive for breast carcinoma, any sub-type.
Exclusion criteria:
- Pacemakers
- Aneurysm clips
- Cochlear implants
- Epicardial pacemaker wires
- Neural stimulators
- Significant claustrophobia
- Significant obesity that would not enable the patient to fit in the scanner
- Pregnancy or breastfeeding
Recruitment
Surgical patients referred by Dr. Kelly Dabbs will undergo a pre-surgical MRI examination providing they meet the study eligibility criteria.
Statistical analysis
N/AP
Stopping Rules
The study will end once the first 100 subjects enrolled have undergone their MRI breast scan.
Data Safety Monitoring Committee
N/AP
- Conditions
- Breast Neoplasms
- Being tested
- MRI
- Keywords
- Magnetic Resonance Imaging, Pathology
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIProcedure or surgery
pre-surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
-assess how MRI of the breast correlates to standard of care which includes ultrasound, mammography, biopsy and surgery
Measured: 2 years
Secondary outcomes (1)
-assess how the MRO correlates to the breast cancer pathology collected at the CCI
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2006 (estimated)
- Study startMar 2006
- Primary completionJan 2010
- Study completionJan 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- AHS Cancer Control Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Cross Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Barbara Campbell, MD, Principal investigator, AHS Cancer Control Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00291304
- Sponsor's protocol ID
- BR-1-0082
- Status last verified
- Jun 2024
- First submitted
- 13 Feb 2006
- Last updated
- 14 Jun 2024
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
- ClinicalTrials.gov ID
- NCT00291304
- Acronym / sponsor ID
- BR-1-0082
- Conditions
- Breast Neoplasms
- Keywords
- Magnetic Resonance Imaging, Pathology
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 72 participants (actual)
- Lead sponsor
- AHS Cancer Control AlbertaUniversity, hospital or other
- Collaborators
- Cross Cancer Institute
- Study start
- Mar 2006
- Primary completion
- Jan 2010 (actual)
- Study completion
- Jan 2010 (actual)
- First posted
- 14 Feb 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Magnetic Resonance Imaging (MRI) is a well known imaging tool for the investigation and diagnosis of breast cancer, used in addition to breast mammograms and ultrasound. Recent publications suggest that MRI may be the best test to use in women who have very dense breasts, have a family history of breast cancer and have had breast cancer and were treated with breast saving measures. MRI has been shown to be a better tool to show multiple breast cancer spots than mammography or ultrasound. The radiologists and the radiology students will have the opportunity to review the MRI scans along with the breast ultrasound and mammography films and the pathology reports from the breast cancer surgery completed at the CCI. This may enable them to learn how the various subtypes of breast cancer look on MRI. The goal is: 1) to gain good breast MRI expertise, giving the Radiology residents a complete diagnostic program. 2) to develop good MRI breast experience, enabling the Cross Cancer Institute to be the centre of excellence for Breast MRI for northern Alberta.
Detailed description
Background Information
In addition to the gold standard imaging of mammography and breast ultrasound, magnetic resonance imaging (MRI) has become a well established investigational modality for the diagnosis and staging of breast cancer. MRI demonstrates increased sensitivity and specificity relative to both mammography and breast ultrasound in the screening of women with an increased risk of breast cancer development (i.e. familial history of disease and / or genetic predisposition) and those who have very dense breast tissue. MRI has also proved to be very sensitive in the detection of multi-focal, multi-centric breast lesions, permitting the accurate staging of disease. However, despite this demonstrated efficacy, the standardization of MRI studies from one Institution to another is often difficult as each Institution will have a standard breast protocol with sequences set in accordance to the manufacturer of the machine and the manner in which the breast examinations have been designed.
At the Cross Cancer Institute (CCI) a breast MRI protocol based on the technical procedures recommended in the literature and personal scanning experience has been developed. However, due to the limited number of patients undergoing breast MRI examinations, our current experience is limited relative to the level of expertise demonstrated in the interpretation of breast ultrasound and mammographic scans. Fortunately, we now have the opportunity to obtain MRI - pathology correlation as Dr. Kelly Dabbs is performing on site breast cancer surgery at the CCI. We propose to obtain an MRI examination of all consented patients prior to their surgical procedure. The MRI results of each patient will then be compared to previous breast imaging (mammography and breast ultrasound) and histopathological specimens to determine the correlative accuracy of MRI with these techniques. To assess whether the size, grade, and presence of lymphovascular invasion or associated ductal carcinoma in situ influence the accuracy of MR imaging, all breast carcinoma subtypes will be included in this study.
As a teaching hospital, the CCI provides mammographic and breast ultrasound training to the Residents and the Diagnostic Radiology Program at the University of Alberta. Although breast MRI should be part of this training program, we currently do not have the necessary volume of breast MRI scans to provide Residents with adequate experience in this modality. The establishment of a breast MRI protocol, one which refers eligible CCI breast cancer patients for a pre-surgery MRI examination, will promote the development of expertise in this area, provide Residents with a comprehensive Breast program and keep the CCI at the leading edge of breast cancer care.
Objectives
Primary Objective: to assess how the MRI of the breast correlates to a standard of care which includes biopsy, surgery, breast ultrasound and mammography.
Secondary Objective: to assess how the MRI correlates to the breast cancer pathology collected at the CCI.
Study Design
A research study is proposed with the above information in mind, whereby Dr. Kelly Dabbs refers consented surgical patients with known breast carcinoma for a pre-surgical breast MRI. The MRI results will then be reviewed along with the mammograms and breast ultrasounds and then correlated to pathology findings. The intent will be to correlate all of the various sub-types of breast carcinoma with MRI, as well as to assess whether or not MRI demonstrates changes dependent upon the extent lymphovascular invasion, the presence of associated ductal carcinoma in situ and the size, cellular composition and grade of the cancer.
Dr. Dabbs will explain the study rational and give the patient a copy of Informed Consent and, for those patients who are willing to undergo the procedure, schedule a MRI at the CCI. It is our aim to accrue 50 patients per year for two years, for a total of 100 patients.
Inclusion / Exclusion Criteria
Inclusion criteria:
- Females ? 18 years of age
- Females referred to Dr. Kelly Dabbs for breast cancer surgery who have pathology positive for breast carcinoma, any sub-type.
Exclusion criteria:
- Pacemakers
- Aneurysm clips
- Cochlear implants
- Epicardial pacemaker wires
- Neural stimulators
- Significant claustrophobia
- Significant obesity that would not enable the patient to fit in the scanner
- Pregnancy or breastfeeding
Recruitment
Surgical patients referred by Dr. Kelly Dabbs will undergo a pre-surgical MRI examination providing they meet the study eligibility criteria.
Statistical analysis
N/AP
Stopping Rules
The study will end once the first 100 subjects enrolled have undergone their MRI breast scan.
Data Safety Monitoring Committee
N/AP
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- females 18 years or older
- females referred to Dr. Kelly Dabbs for breast cancer surgery with pathology positive for breast carcinoma, any subtype
Key exclusion criteria (8 listed)
- pacemakers
- aneurysm clips
- cochlear implants
- epicardial pacemaker wires
- neural stimulators, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIpre-surgery | Procedure or surgery | – |
Primary outcome
-assess how MRI of the breast correlates to standard of care which includes ultrasound, mammography, biopsy and surgery
Time frame: 2 years
1 secondary outcome
-assess how the MRO correlates to the breast cancer pathology collected at the CCI
Time frame: 2 years
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2024.
Related trials for Breast Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Barbara Campbell, MD principal investigator
AHS Cancer Control Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MRI in people with Breast Neoplasms, run by AHS Cancer Control Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
-assess how MRI of the breast correlates to standard of care which includes ultrasound, mammography, biopsy and surgery (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2024; AzTrials last refreshed its copy on 8 Nov 2026.